Finvest
APLS Biotechnology · Biotech · Merger arb · Rare disease · Thesis updated July 1, 2026

Apellis became a deal spread, not a drug bet

01 Running thesis

The stock story changed

Apellis used to be a commercial biotech story. Investors watched whether SYFOVRE could keep growing in geographic atrophy and whether EMPAVELI could expand in rare kidney disease. That changed when Apellis signed a merger agreement with Biogen on March 31, 2026.

The deal terms are simple. Biogen offered $41.00 per share in cash plus one non-transferable contingent value right, or CVR, worth up to $4.00 per share. A CVR is a side contract that pays only if set goals are hit. In this case, the goals depend on future SYFOVRE sales.

The bull case is deal certainty. If the deal closes under the signed agreement, holders get a clear cash price and may later get extra CVR value. Public reports found for this run say Biogen completed the acquisition on May 14, 2026, which would mean the old APLS common stock is no longer a normal public equity bet.

The bear case is that the CVR is hard to value. The latest Apellis filing still described the transaction as subject to tender and regulatory conditions, so this page keeps the internal deal-risk frame. The open tension is timing: current public news points to a completed deal, while the internal thesis record still treats closing mechanics as the key issue.

May 2026→Apellis' Q1 2026 filing shifted the page from a standalone biotech story to a Biogen deal story. The key terms were $41.00 per share in cash plus a CVR worth up to $4.00.
Apr 2026→The amended 2025 10-K added Part III information but did not change the business, financial, or risk view. The Biogen transaction stayed at the center of the thesis.
Feb 2026▼The 2025 10-K showed SYFOVRE net revenue fell to $586.9 million from $611.9 million, despite volume growth. Higher rebates and patient support costs made the franchise look less clean.
Feb 2026▲The Q4 2025 call pointed to strong early EMPAVELI uptake in new kidney indications. Management also said SYFOVRE gross-to-net discounts would move into the high 20% range in 2026.
Oct 2025→Q3 2025 results showed SYFOVRE demand was still present, but free goods and rebates kept revenue flat. EMPAVELI's nephrology launch began to show real revenue contribution.
Jul 2025▲The FDA approval of EMPAVELI for C3G and primary IC-MPGN widened the market opportunity. A $275.0 million upfront payment from Sobi also strengthened the balance sheet.
02 Business model

Two drugs, one buyer

Apellis makes money from U.S. product sales of two pegcetacoplan-based drugs. SYFOVRE treats geographic atrophy, an advanced form of age-related macular degeneration that damages central vision. EMPAVELI treats paroxysmal nocturnal hemoglobinuria, or PNH, plus C3G and primary IC-MPGN, which are rare kidney diseases.

In Q1 2026, Apellis reported $192.0 million of total net product revenue. SYFOVRE produced $150.7 million. EMPAVELI produced $41.3 million. That makes SYFOVRE the main economic engine and the key input for any CVR payout.

If Biogen ownership is completed, Apellis stops being a standalone operating company for public shareholders. The drugs and pipeline move inside Biogen. For former Apellis holders, the business model becomes a cash payout already received plus a possible future CVR payout.

03 Product portfolio

What Biogen wanted

Cash cow

SYFOVRE

SYFOVRE is Apellis' largest product. It treats geographic atrophy secondary to age-related macular degeneration and generated $150.7 million of U.S. net product revenue in Q1 2026.

Steady

EMPAVELI for PNH

EMPAVELI is approved for PNH, a rare blood disorder where red blood cells break down too easily. The franchise faces competition, including oral products noted in prior filings.

Growth engine

EMPAVELI for C3G and primary IC-MPGN

EMPAVELI was expanded into C3G and primary IC-MPGN in 2025. Management had described the kidney launch as a key growth driver before the Biogen deal took over the investment story.

Option

SYFOVRE pre-filled syringe

Apellis planned to submit a single-dose pre-filled syringe for regulatory approval in the first half of 2026. The goal is fewer steps for retina doctors when giving the eye injection.

Option

SYFOVRE plus APL-3007

This is a next-generation geographic atrophy program that combines SYFOVRE with APL-3007, an siRNA. It entered Phase 2 testing in June 2025.

Option

Beam Therapeutics gene-editing program

Apellis is also advancing a gene-editing program with Beam Therapeutics aimed at the neonatal Fc gamma receptor. This is earlier-stage science and not the near-term driver of deal value.

04 Business segments

Revenue is mostly SYFOVRE

SYFOVRE78%flat
EMPAVELI22%growing fast

The mix uses Q1 2026 U.S. net product revenue from Apellis' Form 10-Q. SYFOVRE was about 78% of product sales, so the company and the CVR remain highly tied to one eye drug.

05 Risk factors

What can still go wrong

Deal status mismatch

High impact · Medium odds

The latest Apellis filing on file framed the Biogen deal as pending and subject to conditions. Public reports found for this run say Biogen completed the acquisition on May 14, 2026. If a data source still shows APLS trading like a normal stock, investors should treat that as a possible stale quote or corporate-action issue.

We watchCheck Nasdaq trading status, Biogen deal completion notices, and any broker treatment of APLS shares or CVRs.

CVR pays zero

High impact · Medium odds

The CVR can pay up to $4.00 per share, but only if SYFOVRE reaches large future sales milestones. The internal thesis cites $1.5 billion and $2.0 billion SYFOVRE sales bars. If Biogen cannot drive enough demand, the CVR may have no value.

We watchTrack Biogen's reported SYFOVRE sales and any CVR milestone updates from 2027 through 2031.

SYFOVRE pricing pressure

Medium impact · High odds

Before the deal, Apellis reported that SYFOVRE revenue was being held back by higher rebates, free goods, and patient support costs. The 2025 10-K showed SYFOVRE net revenue fell to $586.9 million from $611.9 million the year before, even with volume growth. That pressure matters because SYFOVRE is the drug tied to the CVR.

We watchWatch gross-to-net discounts, rebate comments, free goods usage, and payer coverage for SYFOVRE.

Commercial disruption after takeover

Medium impact · Medium odds

A merger can distract sales teams, unsettle employees, and slow work with doctors or partners. Apellis warned that the pending transaction could hurt employee retention and relationships. If the takeover is complete, the risk shifts to whether Biogen can integrate the assets without slowing sales.

We watchListen for Biogen comments on salesforce retention, retina doctor access, and nephrology launch momentum.

Litigation and contract costs

Medium impact · Low odds

Apellis warned that merger-related lawsuits could add costs or delay the transaction. The merger agreement also included a $205.0 million termination fee payable to Biogen in certain cases. This matters most if deal completion or deal validity is questioned.

We watchMonitor merger litigation dockets, SEC filings, and any notice about termination fee claims.
06 Quick answers

In one breath

Is Apellis still a public company?

The latest internal Apellis thesis still frames the Biogen deal as the main pending event. Public reports found for this run say Biogen completed the acquisition on May 14, 2026, and Apellis became a Biogen subsidiary.

What did Apellis shareholders get in the Biogen deal?

The signed deal offered $41.00 per share in cash plus one non-transferable CVR worth up to $4.00 per share. The CVR depends on future SYFOVRE sales milestones.

Why does SYFOVRE matter so much?

SYFOVRE generated $150.7 million of Apellis' $192.0 million Q1 2026 net product revenue. It is also the drug tied to the CVR payout, so future sales decide whether former holders get more money.

What is EMPAVELI?

EMPAVELI is a pegcetacoplan drug used for PNH and rare kidney diseases called C3G and primary IC-MPGN. It generated $41.3 million of U.S. net product revenue in Q1 2026.